Summary:
- This article discusses a study on the use of a new targeted therapy drug called trastuzumab deruxtecan (T-DXd) for the treatment of HER2-positive breast cancer.
- The study found that T-DXd significantly improved progression-free survival and overall survival compared to the standard treatment, trastuzumab emtansine (T-DM1), in patients with HER2-positive metastatic breast cancer.
- The results suggest that T-DXd could be a more effective treatment option for patients with HER2-positive breast cancer that has spread to other parts of the body.